The Japan next-generation sequencing market size was valued at USD 458.3 Million in 2025 and is projected to grow at a CAGR of 17.24% from 2024 to 2033. Key drivers of this growth include the declining costs associated with genetic sequencing and significant advancements in cloud computing and data integration technologies. Moreover, rising investments in cancer treatment and the broad application of next-generation sequencing (NGS) in cancer diagnosis and therapy are expected to propel market expansion further.
Government-backed precision medicine initiatives further accelerate this trend by promoting the integration of NGS into mainstream clinical practice. National programs like the Cancer Genomic Medicine Program, established by Japan’s Ministry of Health, Labour and Welfare, have appointed specialized cancer genome medical centers across the country, ensuring equitable access to advanced sequencing-based diagnostics. Additionally, companion diagnostics for targeted therapies are increasingly gaining approval from Japan’s regulatory authorities, which boosts the clinical demand for NGS technologies. Since oncology remains the largest application area for NGS in Japan, the combined effect of rising cancer rates and supportive government precision medicine efforts is a strong driver of market growth.
The country’s regulatory framework has progressed to support faster and smoother integration of NGS into research and clinical workflows. The Pharmaceuticals and Medical Devices Agency (PMDA) has established clear approval pathways for NGS-based diagnostic panels and companion diagnostics, lowering barriers for academic groups and industry researchers to develop new assays and platforms. These supportive policies foster collaborations among universities, hospitals, and biotechnology companies, creating a thriving research ecosystem. The alignment of government funding, regulatory support, and institutional participation makes Japan one of the most research-intensive markets for NGS worldwide, establishing it as a hub for genomics-driven innovation in Asia.
This product will be delivered within 2 business days.
Rising Cancer Burden & Precision Medicine Initiatives
Japan faces some of the highest cancer rates and death rates worldwide, which continue to put a lot of pressure on its healthcare system. This increasing burden creates a strong need for advanced diagnostic tools that allow early detection, accurate characterizations of tumors, and improved treatment choices. Next-generation sequencing (NGS) has become a key technology in this effort, as it enables detailed genomic profiling of tumors, identification of actionable mutations, and monitoring of disease progression through liquid biopsies. The clinical usefulness of NGS in oncology is gaining recognition across Japan’s hospitals and cancer research centers, leading to broader adoption in routine cancer diagnostics.Government-backed precision medicine initiatives further accelerate this trend by promoting the integration of NGS into mainstream clinical practice. National programs like the Cancer Genomic Medicine Program, established by Japan’s Ministry of Health, Labour and Welfare, have appointed specialized cancer genome medical centers across the country, ensuring equitable access to advanced sequencing-based diagnostics. Additionally, companion diagnostics for targeted therapies are increasingly gaining approval from Japan’s regulatory authorities, which boosts the clinical demand for NGS technologies. Since oncology remains the largest application area for NGS in Japan, the combined effect of rising cancer rates and supportive government precision medicine efforts is a strong driver of market growth.
Supportive Government Policies & Genomic Programs
The Japanese government has played a key role in increasing the use of next-generation sequencing (NGS) technologies by creating a supportive research and regulatory environment. National initiatives like the Japan Genomic Medicine Program and the Cancer Genomic Medicine Promotion Plan have allocated significant funding for large-scale genomic research, including population-based genome sequencing projects and clinical cancer genome studies. These programs aim to boost academic research and develop strong databases that form the basis for translational medicine, biomarker discovery, and new therapeutic development. By investing in infrastructure such as cancer genome sequencing centers and national biobanks, Japan enables researchers to access high-quality genomic data that speed up discoveries in disease mechanisms and personalized treatments.The country’s regulatory framework has progressed to support faster and smoother integration of NGS into research and clinical workflows. The Pharmaceuticals and Medical Devices Agency (PMDA) has established clear approval pathways for NGS-based diagnostic panels and companion diagnostics, lowering barriers for academic groups and industry researchers to develop new assays and platforms. These supportive policies foster collaborations among universities, hospitals, and biotechnology companies, creating a thriving research ecosystem. The alignment of government funding, regulatory support, and institutional participation makes Japan one of the most research-intensive markets for NGS worldwide, establishing it as a hub for genomics-driven innovation in Asia.
Japan Next Generation Sequencing Market Report Segmentation
This report forecasts revenue growth at country level and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, the analyst has segmented the Japan next generation sequencing market on the basis of technology, product, end use, workflow, and application:- Technology Outlook (Revenue in USD Million, 2021-2033)
- Whole Genome Sequencing
- Whole Exome Sequencing
- Targeted Sequencing & Resequencing
- Others
Product Outlook (Revenue, USD Million, 2021-2033)
- Consumables
- Platforms
Application Outlook (Revenue, USD Million, 2021-2033)
- Oncology
- Clinical Investigation
- Reproductive Health
- HLA Typing/Immune System Monitoring
- Metagenomics, Epidemiology & Drug Development
- Agrigenomics & Forensics
- Consumer Genomics
Workflow Outlook (Revenue, USD Million, 2021-2033)
- Pre-Sequencing
- Sequencing
- NGS Data Analysis
End Use Outlook (Revenue, USD Million, 2021-2033)
- Academic Research
- Clinical Research
- Hospitals & Clinics
- Pharma & Biotech Entities
- Other users
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Japan Next Generation Sequencing Market Variables, Trends & Scope
Chapter 4. Japan Next Generation Sequencing Market: Technology Business Analysis
Chapter 5. Japan Next Generation Sequencing Market: Product Business Analysis
Chapter 6. Japan Next Generation Sequencing Market: Application Business Analysis
Chapter 7. Japan Next Generation Sequencing Market: Workflow Business Analysis
Chapter 8. Japan Next Generation Sequencing Market: End Use Business Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this Japan Next Generation Sequencing market report include:- Illumina, Inc
- QIAGEN
- Thermo Fisher Scientific, Inc
- BGI
- Pacific Biosciences
- Bio Rad Laboratories
- Oxford Nanopore Technologies, Inc
- Myriad Genetics. Inc.
- Agilent Technologies Inc
- Eurofins Scientific
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 80 |
| Published | September 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 458.3 Million |
| Forecasted Market Value ( USD | $ 1640 Million |
| Compound Annual Growth Rate | 17.2% |
| Regions Covered | Japan |
| No. of Companies Mentioned | 11 |
